Loading...
•
Dec 31, 2023
EyePoint Pharmaceuticals Q4 2023 Earnings Report
EyePoint Pharmaceuticals reported financial results for Q4 2023, highlighting positive data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD and the strengthening of the balance sheet.
Key Takeaways
EyePoint Pharmaceuticals reported total net revenue of $14.0 million for the quarter ended December 31, 2023, compared to $10.5 million for the same period in 2022. The company's cash and investments reached $331 million, expected to fund operations through topline data for Phase 3 trials of EYP-1901 for wet AMD in 2026.
Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD, achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024.
Dosed first patient in Phase 2 VERONA clinical trial of EYP-1901 in DME; topline data expected in 1Q 2025.
Phase 2 PAVIA clinical trial topline data of EYP-1901 in moderately severe-to-severe NPDR anticipated in 2Q 2024.
Appointed Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer.
Revenue by Segment
Forward Guidance
EyePoint Pharmaceuticals expects that its cash, cash equivalents, and investments on December 31, 2023, will enable it to fund operations through topline data for the planned Phase 3 clinical trials of EYP-1901 for wet AMD in 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...